ArticleHuman genomics2026
Concurrent physiologic and gene-based genetic newborn hearing screening in a general population.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPhysiologic newborn hearing screening (NBHS) has several weaknesses requiring improvement. Studies have explored variant-based genetic NBHS as a complement to physiologic NBHS. However, this genetic NBHS strategy has fundamental limitations that challenge logistics.
methodsGiven findings that a small set of genes accounts for the majority of genetic etiologies of hearing loss (HL), we designed a gene-based genetic NBHS strategy that screens for genes instead of limited variants, targeting the coding regions of twelve HL-related genes and the aminoglycoside-induced HL risk gene MT-RNR1. Our cohort study was conducted at Nanjing Women and Children’s Healthcare Hospital in China, between March 2022 and July 2023. All participants were offered concurrent physiologic and gene-based genetic NBHS. Infants with positive physiologic or genetic NBHS results were scheduled for audiological assessments.
resultsOf 20,997 participants with eligible physiologic and genetic NBHS results, 164 (0.8%) had positive physiologic or genetic NBHS results. Of 150 who underwent audiological assessments, 77 had confirmed HL. Among them, 32 were identified by genetic NBHS only, 24 by both physiologic and genetic NBHS, and 21 by physiologic NBHS only. Compared with conventional physiologic NBHS protocol (identified 45 HL cases), incorporating gene-based genetic NBHS into physiologic NBHS (additionally identified 32 HL cases) only required an additional 0.4% (87/20,997) of infants to undergo audiological assessments, yet achieved a 71% (32/45) increase in HL identification and provided genetic etiological information for 73% (56/77) of all HL cases. For 21 HL cases identified by physiologic NBHS only, genome sequencing identified genetic findings in three additional cases, showing that up to 77% (59/77) of infants with HL were caused by genetic factors in this general newborn population.
conclusionsOur new comprehensive NBHS protocol, concurrent physiologic and gene-based genetic NBHS, significantly improved the identification of infants with HL. The results demonstrated that the gene-based genetic NBHS addressed fundamental limitations of the variant-based strategy and was a powerful complement to physiologic NBHS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.